
-
MacIntyre 'will not back off' in bid for first major title
-
What's in the EU's two-trillion-euro budget bazooka?
-
Barca's planned Camp Nou return in August scrapped
-
McIlroy 'excited' for shot at homecoming British Open glory
-
Hunter Harman stalking second British Open crown
-
Marquez tops Czech MotoGP practice as Martin returns
-
Disinformation catalyses anti-migrant unrest in Spain
-
Ex-Brazil president Bolsonaro must wear monitoring device: Supreme Court
-
Resilient US economy spurs on stock markets
-
Man Utd agree deal to sign Brentford winger Mbeumo: reports
-
New clashes rock Syria's Druze heartland as tribal fighters reinforce Bedouin
-
Germany presses ahead with deportations to Afghanistan
-
Crews rescue 18 miners trapped in Colombia
-
McIlroy five back as Harman leads British Open
-
Lyles the showman ready to deliver 100m entertainment
-
EU targets Russian oil in tough new Ukraine war sanctions
-
Liverpool line up swoop for Frankfurt striker Ekitike: reports
-
Stocks up, dollar down tracking Trump moves and earnings
-
Three Sri Lankan elephants killed in blow to conservation efforts
-
Indie game studios battle for piece of Switch 2 success
-
Former Liverpool and Man Utd star Ince banned for drink-driving
-
Spain taming fire that belched smoke cloud over Madrid
-
Top Holy Land clerics visit Gaza after deadly church strike
-
Scotland end tour with seven-try thrashing of Samoa
-
Sharaa's pullout from Syria Druze heartland exposes shaky leadership
-
Trump team to seek release of Epstein documents
-
Wrexham chief wants playoff push after promotion to Championship
-
Snoop Dogg becomes co-owner of Championship club Swansea
-
Pakistan bans new hotel construction around tourist lakes
-
Trump's budget hacksaw leaves public broadcasting on precipice
-
New deep sea mining rules lack consensus despite US pressure
-
North Korea bars foreign tourists from new seaside resort
-
Lions ignoring the noise ahead of Wallabies Test
-
CBS says Stephen Colbert's 'The Late Show' to end in May 2026
-
Lions block Wallabies flanker Samu from Pasifika team
-
Indian state blames cricket team for deadly stampede
-
Serbian youth pumps up protest at last EXIT festival
-
US Congress approves $9 bn in Trump cuts to foreign aid, public media
-
Misbehaving monks: Sex scandal shakes Thai Buddhist faithful
-
Injury rules All Blacks wing Ioane out of third France Test
-
China mulls economy-boosting measures to counter 'severe situation'
-
Wallabies skipper Wilson concedes losing Valetini a massive blow
-
Asian markets on course to end week on a positive note
-
UK 'princes in the tower' murder probe clears Richard III
-
From Antarctica to Brussels, hunting climate clues in old ice
-
Springboks pick dynamic half-backs for final Championship warm-up
-
Jorge Martin returns to MotoGP racing at revamped Brno
-
Olympic champion Lyles to make 100m season debut at London Diamond League
-
Japan's SMEs ready to adapt to Trump tariffs
-
South Korea to end private adoptions after landmark probe

3M expects to sell fewer Covid-19 masks this year
After seeing sales of medical masks soar during the Covid-19 pandemic, US manufacturer 3M warned Monday that demand is expected to slow sharply this year.
The warning echoes that of other companies like vaccine-maker Pfizer and the CVS drugstore chain that have said pandemic-related sales are likely to soften.
After Covid-19 broke out in 2020, 3M, a conglomerate that makes a wide range of products from Post-it notes to air filters, quickly ramped up output of face masks, which became ubiquitous.
But in its quarterly earnings report Monday, 3M forecast a "decline in Covid-related respirator demand" which it said will weigh on overall sales growth and also dampen earnings.
Honeywell in early February said it sold fewer masks in the fourth quarter compared to the same period in 2020, and sees the slowdown continuing this year, hitting the company's overall sales.
Pfizer, whose vaccine developed with German company BioNTech was the first approved in the United States to counter the deadly virus, warned last week that sales of the jabs would slow in 2022.
But the US pharmaceutical group expects to see sales of its Covid-19 treatment pill to jump to at least $22 billion.
Meanwhile, CVS, which conducted 32 million Covid tests and administered more than 59 million vaccines in 2021, said last week it is expecting vaccinations to drop by 70 to 80 percent and testing to fall by as much as 50 percent.
CVS Chief financial officer Shawn Guertin told analysts the chain should see a "modest" uptick in sales of over-the-counter test kits.
S.Pimentel--PC